Abstract
This study compared the calculated vancomycin area under the curve (AUC0-24)using trapezoidal and non-trapezoidal first-order pharmacokinetic equations. This retrospective observational study included adult patients with documented MRSA bacteremia who received ≥ 48 h of intravenous vancomycin and had two consecutive serum levels after the first dose. AUC0-24 was calculated using trapezoidal and non-trapezoidal equations. Correlation and agreement between methods were assessed using Pearson's correlation coefficient (r) and Bland-Altman plots. Significant predictors (p < 0.05) from simple linear regression were included in a multiple linear regression model to evaluate their impact on AUC0-24 for both methods. Fifty-two patients were included. The median age was 63 years (interquartile range [IQR]: 50-73), and the median vancomycin clearance was 4 l/h (IQR: 2-6). Median vancomycin AUC0-24 was 399 mg∙h/l (IQR: 257-674) for the trapezoidal method and 572 mg∙h/l (IQR: 466-807) for the non-trapezoidal method. There was a strong correlation between the methods (r = 0.87 [95% CI, 0.79-1]; P < 0.01), but Bland-Altman analysis showed poor agreement, with a bias of -198 mg∙h/l and 95% limits of agreement from -482 to 86 mg∙h/l. In multiple linear regression, total daily dose and vancomycin clearance were independent predictors of AUC0-24 for both methods, with a stronger impact on non-trapezoidal AUC0-24 (adjusted R2 = 0.70) than trapezoidal AUC0-24 (adjusted R2 = 0.59). Trapezoidal and non-trapezoidal equations are not interchangeable for estimating vancomycin AUC0-24. The trapezoidal method consistently results in lower AUC0-24 estimates than the non-trapezoidal method.
Published Version (
Free)
Join us for a 30 min session where you can share your feedback and ask us any queries you have